PDGFRA and neoplasm: However, there are many ways for tumours to acquire resistance, and recently it has been shown that changes to the regulatory chromatin landscape can permit resistance in several scenarios, including endocrine resistance in breast cancer [13], BET inhibitor resistance in acute myeloid leukaemia [47], and PDGFRA inhibitor resistance in glioblastoma [48].